CXCR3 and B-cell chronic lymphocytic leukemia: In particular, CXCR4 was increased by the treatment with Bafetinib and Ibrutinib, while CCR7 was reduced by Bafetinib; at the same time, CXCR5 was affected only by Ibrutinib and the two kinase inhibitors do not show a significant influence on CXCR3 expression, suggesting that their action may be carried out mostly by the receptors involved in the process of CLL homing.